why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $4.00
ImmunityBio Inc [NASDAQ: IBRX] price surged by 11.97 percent to reach at $0.56. The company report on February 21, 2024 at 9:00 AM that ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized